- Home
- PERI vs ANL Comparison
PERI vs ANL Comparison
Compare PERI & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PERI | ANL |
|---|---|---|
| Founded | 1999 | 2004 |
| Country | Israel | Cayman Islands |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 412.5M | 406.5M |
| IPO Year | 2005 | 2022 |
Fundamental Metrics
Financial Performance| Metric | PERI | ANL |
|---|---|---|
| Price | $9.82 | $8.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $14.50 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 432.7K | 197.1K |
| Earning Date | 05-12-2026 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.95 | N/A |
| Revenue Next Year | $1.07 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.00 | $0.88 |
| 52 Week High | $11.44 | $12.09 |
Technical Indicators
Market Signals| Indicator | PERI | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 61.03 | 56.42 |
| Support Level | $9.14 | $1.36 |
| Resistance Level | $10.25 | $9.98 |
| Average True Range (ATR) | 0.41 | 0.86 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 65.99 | 69.17 |
Price Performance
Historical ComparisonAbout PERI Perion Network Ltd.
Perion Network Ltd is a technology company. It offers online advertising and search solutions to brands, agencies, and publishers through desktop, mobile, and social channels. It connects advertisers to consumers across digital advertising channels, including search advertising, social, display, video, digital audio, digital out of home (DOOH), and Connected TV (CTV) advertising. The company earns prime revenue from search advertising and display advertising services. It operates in the business segment of High Impact Advertising solutions. Geographically, the company generates a majority of its revenue from the United States and the rest from other regions.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.